750
Participants
Start Date
August 31, 2025
Primary Completion Date
August 31, 2027
Study Completion Date
August 31, 2030
Targeted drugs combined with anti-PD-1/PD-L1 antibodies
Targeted drugs combined with anti-PD-1/PD-L1 antibodies
TACE (transarterial chemoembolization) combined with targeted/immunotherapy
TACE (transarterial chemoembolization) combined with targeted/immunotherapy
Lenvatinib monotherapy
For patients weighing less than 60 kg, the recommended daily dose of this product is 8 mg (2 capsules of 4 mg), once daily; For patients weighing ≥ 60 kg, the recommended daily dose of this product is 12 mg (3 capsules of 4 mg), once daily. Treatment should be continued until disease progression or intolerable toxic reactions occur.
Huaier granules combined with any of the above Cohorts for treatment
Oral administration of Huaier granules, 10g each time, 3 times a day, until the end of the study, intolerable toxicity, withdrawal from the study for any reason, or death, whichever occurs first; Or the researcher determines that there is no longer any benefit.It is recommended that the date of first use of Huaier granules be determined by the researchers, and after disease progression, the researchers and patients should jointly decide whether to continue receiving Huaier granules treatment.
LinkDoc Technology (Beijing) Co. Ltd.
INDUSTRY
Huazhong University of Science and Technology
OTHER
Fudan University
OTHER